Centanafadine’s Route to FDA Review: A Clinical Path of the ADHD Medication
Centanafadine, a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI), awaits a regulatory decision by the US Food and Drug Administration (FDA) on Friday, July 24. Ahead of the FDA action, review the path of Otsuka Pharmaceutical’s centanafadine for treatment of ADHD.
Other Articles in this Edition
Next steps after your child is diagnosed with ADHD
New study links ADHD symptoms in boys and addictive social media use
At What Age Should Your Neurodivergent Child Get a Cell Phone?
They watched TikToks about ADHD, anxiety and cancer. Then they worried they had them
What is ‘popcorn brain’ and how to help it
What Is Your Building Communicating to Students?
How telehealth is fuelling a surge in ADHD scripts in a business model that benefits the rich
New Meta-analysis Finds Structured Executive Function Training Largely Ineffective
Study Maps Accelerated Brain Aging Signatures Across 9 Conditions
Centanafadine’s Route to FDA Review: A Clinical Path of the ADHD Medication